{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T03:20:01Z","timestamp":1788232801297,"version":"build-2803163510"},"reference-count":34,"publisher":"Elsevier BV","issue":"11","license":[{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,9,18]],"date-time":"2025-09-18T00:00:00Z","timestamp":1758153600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100006483","name":"AbbVie Inc","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006483","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["jpharmsci.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Pharmaceutical Sciences"],"published-print":{"date-parts":[[2025,11]]},"DOI":"10.1016\/j.xphs.2025.103999","type":"journal-article","created":{"date-parts":[[2025,9,19]],"date-time":"2025-09-19T14:41:20Z","timestamp":1758292880000},"page":"103999","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Correlating high concentration behavior of commercial or clinical-stage monoclonal and bispecific antibodies with miniaturized polyethylene glycol precipitation assay"],"prefix":"10.1016","volume":"114","author":[{"given":"Sadisna","family":"Shahi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mahsa","family":"Azami","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richa","family":"Garg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rajeeva","family":"Singh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3787-9173","authenticated-orcid":false,"given":"Chen","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.xphs.2025.103999_bib0001","doi-asserted-by":"crossref","DOI":"10.1080\/19420862.2023.2185924","article-title":"Blueprint for antibody biologics developability","volume":"15","author":"Mieczkowski","year":"2023","journal-title":"mAbs"},{"issue":"5","key":"10.1016\/j.xphs.2025.103999_bib0002","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1517\/14712598.2016.1150996","article-title":"\"NextGen\" biologics: bispecific antibodies and emerging clinical results","volume":"16","author":"Thakur","year":"2016","journal-title":"Expert Opin Biol Ther"},{"issue":"2","key":"10.1016\/j.xphs.2025.103999_bib0003","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/j.autrev.2018.07.014","article-title":"Bispecific antibodies: the next generation of targeted inflammatory bowel disease therapies","volume":"18","author":"Peyrin-Biroulet","year":"2019","journal-title":"Autoimmun Rev"},{"issue":"7","key":"10.1016\/j.xphs.2025.103999_bib0004","doi-asserted-by":"crossref","first-page":"2590","DOI":"10.1016\/j.xphs.2021.03.017","article-title":"A review of formulations of commercially available antibodies","volume":"110","author":"Strickley","year":"2021","journal-title":"J Pharm Sci"},{"issue":"1","key":"10.1016\/j.xphs.2025.103999_bib0005","doi-asserted-by":"crossref","DOI":"10.1080\/19420862.2023.2211185","article-title":"High concentration formulation developability approaches and considerations","volume":"15","author":"Zarzar","year":"2023","journal-title":"mAbs"},{"issue":"4","key":"10.1016\/j.xphs.2025.103999_bib0006","first-page":"262","article-title":"US FDA-approved therapeutic antibodies with high-concentration formulation: summaries and perspectives","volume":"4","author":"Wang","year":"2021","journal-title":"Antib Ther"},{"key":"10.1016\/j.xphs.2025.103999_bib0007","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1016\/j.ejpb.2017.06.029","article-title":"High-concentration protein formulations: how high is high?","volume":"119","author":"Garidel","year":"2017","journal-title":"Eur J Pharm Biopharm"},{"issue":"1","key":"10.1016\/j.xphs.2025.103999_bib0008","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1002\/jps.21797","article-title":"Understanding and modulating opalescence and viscosity in a monoclonal antibody formulation","volume":"99","author":"Salinas","year":"2010","journal-title":"J Pharm Sci"},{"issue":"5","key":"10.1016\/j.xphs.2025.103999_bib0009","doi-asserted-by":"crossref","first-page":"1431","DOI":"10.1021\/acs.molpharmaceut.5b00937","article-title":"Pharmaceutical perspective on opalescence and liquid\u2013Liquid phase separation in protein solutions","volume":"13","author":"Raut","year":"2016","journal-title":"Mol Pharm"},{"issue":"8","key":"10.1016\/j.xphs.2025.103999_bib0010","doi-asserted-by":"crossref","first-page":"1118","DOI":"10.1002\/pro.2289","article-title":"Application of a PEG precipitation method for solubility screening: a tool for developing high protein concentration formulations","volume":"22","author":"Li","year":"2013","journal-title":"Protein Sci"},{"issue":"5","key":"10.1016\/j.xphs.2025.103999_bib0011","doi-asserted-by":"crossref","first-page":"1431","DOI":"10.1021\/acs.molpharmaceut.5b00937","article-title":"Pharmaceutical perspective on opalescence and liquid-liquid phase separation in protein solutions","volume":"13","author":"Raut","year":"2016","journal-title":"Mol Pharm"},{"key":"10.1016\/j.xphs.2025.103999_bib0012","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/j.ab.2014.11.016","article-title":"Concomitant Raman spectroscopy and dynamic light scattering for characterization of therapeutic proteins at high concentrations","volume":"472","author":"Zhou","year":"2015","journal-title":"Anal Biochem"},{"issue":"2","key":"10.1016\/j.xphs.2025.103999_bib0013","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1016\/j.ab.2008.03.032","article-title":"Measurement of the second osmotic virial coefficient for protein solutions exhibiting monomer-dimer equilibrium","volume":"377","author":"Alford","year":"2008","journal-title":"Anal Biochem"},{"issue":"1","key":"10.1016\/j.xphs.2025.103999_bib0014","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-021-01126-4","article-title":"An open-source automated PEG precipitation assay to measure the relative solubility of proteins with low material requirement","volume":"11","author":"Oeller","year":"2021","journal-title":"Sci Rep"},{"issue":"11","key":"10.1016\/j.xphs.2025.103999_bib0015","doi-asserted-by":"crossref","first-page":"1947","DOI":"10.1007\/s11095-021-03119-4","article-title":"Revisit PEG-induced precipitation assay for protein solubility assessment of monoclonal antibody formulations","volume":"38","author":"Scannell","year":"2021","journal-title":"Pharm Res"},{"issue":"4","key":"10.1016\/j.xphs.2025.103999_bib0016","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1080\/19420862.2019.1589851","article-title":"Development of a high-throughput solubility screening assay for use in antibody discovery","volume":"11","author":"Chai","year":"2019","journal-title":"mAbs"},{"issue":"1","key":"10.1016\/j.xphs.2025.103999_bib0017","doi-asserted-by":"crossref","DOI":"10.1080\/19420862.2023.2256745","article-title":"Development of in silico models to predict viscosity and mouse clearance using a comprehensive analytical data set collected on 83 scaffold-consistent monoclonal antibodies","volume":"15","author":"Mock","year":"2023","journal-title":"mAbs"},{"issue":"11","key":"10.1016\/j.xphs.2025.103999_bib0018","doi-asserted-by":"crossref","first-page":"1671","DOI":"10.1023\/A:1016201319136","article-title":"Estimation of recombinant bovine somatotropin solubility by excluded-volume interaction with polyethylene glycols","volume":"12","author":"Stevenson","year":"1995","journal-title":"Pharm Res"},{"issue":"11","key":"10.1016\/j.xphs.2025.103999_bib0019","doi-asserted-by":"crossref","first-page":"5842","DOI":"10.1021\/acs.molpharmaceut.3c00694","article-title":"Predicting colloidal stability of high-concentration monoclonal antibody formulations in common pharmaceutical buffers using improved polyethylene glycol induced protein precipitation assay","volume":"20","author":"Meza","year":"2023","journal-title":"Mol Pharm"},{"key":"10.1016\/j.xphs.2025.103999_bib0020","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1007\/978-1-4939-9678-0_3","article-title":"Quantitative evaluation of protein solubility in aqueous solutions by PEG-induced liquid\u2013Liquid phase separation","author":"Wang","year":"2019","journal-title":"Protein Self-Assembly: Methods and Protocols"},{"issue":"5","key":"10.1016\/j.xphs.2025.103999_bib0021","doi-asserted-by":"crossref","first-page":"1391","DOI":"10.1021\/mp400521b","article-title":"Quantitative evaluation of colloidal stability of antibody solutions using PEG-induced liquid\u2013Liquid phase separation","volume":"11","author":"Wang","year":"2014","journal-title":"Mol Pharm"},{"key":"10.1016\/j.xphs.2025.103999_bib0022","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/j.ab.2014.11.016","article-title":"Concomitant Raman spectroscopy and dynamic light scattering for characterization of therapeutic proteins at high concentrations","volume":"472","author":"Zhou","year":"2015","journal-title":"Anal Biochem"},{"key":"10.1016\/j.xphs.2025.103999_bib0023","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.ejpb.2020.03.011","article-title":"Relationship of PEG-induced precipitation with protein-protein interactions and aggregation rates of high concentration mAb formulations at 5 \u00b0C","volume":"151","author":"W\u00e4lchli","year":"2020","journal-title":"Eur J Pharm Biopharm"},{"issue":"1","key":"10.1016\/j.xphs.2025.103999_bib0024","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/S0141-8130(96)01150-6","article-title":"Destabilization of human serum albumin by polyethylene glycols studied by thermodynamical equilibrium and kinetic approaches","volume":"20","author":"Farruggia","year":"1997","journal-title":"Int J Biol Macromol"},{"issue":"1","key":"10.1016\/j.xphs.2025.103999_bib0025","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/S0141-8130(99)00061-6","article-title":"Thermal features of the bovine serum albumin unfolding by polyethylene glycols","volume":"26","author":"Farruggia","year":"1999","journal-title":"Int J Biol Macromol"},{"issue":"1","key":"10.1016\/j.xphs.2025.103999_bib0026","doi-asserted-by":"crossref","DOI":"10.1208\/ps060104","article-title":"Polyethylene glycol-induced precipitation of interferon alpha-2a followed by vacuum drying: development of a novel process for obtaining a dry, stable powder","volume":"6","author":"Sharma","year":"2004","journal-title":"AAPS PharmSci"},{"issue":"8","key":"10.1016\/j.xphs.2025.103999_bib0027","doi-asserted-by":"crossref","first-page":"2319","DOI":"10.1016\/j.xphs.2016.05.021","article-title":"A micro\u2013Polyethylene glycol precipitation assay as a relative solubility screening tool for monoclonal antibody design and formulation development","volume":"105","author":"Toprani","year":"2016","journal-title":"J Pharm Sci"},{"issue":"2","key":"10.1016\/j.xphs.2025.103999_bib0028","first-page":"426","article-title":"Advancing therapeutic protein discovery and development through comprehensive computational and biophysical characterization","volume":"17","author":"Gentiluomo","year":"2020","journal-title":"Mol Pharm"},{"issue":"32","key":"10.1016\/j.xphs.2025.103999_bib0029","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.abb0372","article-title":"A single molecular descriptor to predict solution behavior of therapeutic antibodies","volume":"6","author":"Kingsbury","year":"2020","journal-title":"Sci Adv"},{"issue":"9","key":"10.1016\/j.xphs.2025.103999_bib0030","doi-asserted-by":"crossref","first-page":"1325","DOI":"10.1023\/A:1025771421906","article-title":"Physical stability of proteins in aqueous solution: mechanism and driving forces in nonnative protein aggregation","volume":"20","author":"Chi","year":"2003","journal-title":"Pharm Res"},{"issue":"5","key":"10.1016\/j.xphs.2025.103999_bib0031","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1110\/ps.0235703","article-title":"Roles of conformational stability and colloidal stability in the aggregation of recombinant human granulocyte colony-stimulating factor","volume":"12","author":"Chi","year":"2003","journal-title":"Protein Sci"},{"issue":"1","key":"10.1016\/j.xphs.2025.103999_bib0032","doi-asserted-by":"crossref","DOI":"10.1080\/19420862.2024.2394229","article-title":"Developability considerations for bispecific and multispecific antibodies","volume":"16","author":"Amash","year":"2024","journal-title":"MAbs"},{"key":"10.1016\/j.xphs.2025.103999_bib0033","first-page":"285","author":"Gokarn","year":"2015"},{"issue":"1\u20132","key":"10.1016\/j.xphs.2025.103999_bib0034","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.bpc.2006.12.007","article-title":"Suppression of protein interactions by arginine: a proposed mechanism of the arginine effects","volume":"127","author":"Arakawa","year":"2007","journal-title":"Biophys Chem"}],"container-title":["Journal of Pharmaceutical Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022354925004538?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022354925004538?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,1,29]],"date-time":"2026-01-29T19:04:44Z","timestamp":1769713484000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0022354925004538"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11]]},"references-count":34,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2025,11]]}},"alternative-id":["S0022354925004538"],"URL":"https:\/\/doi.org\/10.1016\/j.xphs.2025.103999","relation":{},"ISSN":["0022-3549"],"issn-type":[{"value":"0022-3549","type":"print"}],"subject":[],"published":{"date-parts":[[2025,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Correlating high concentration behavior of commercial or clinical-stage monoclonal and bispecific antibodies with miniaturized polyethylene glycol precipitation assay","name":"articletitle","label":"Article Title"},{"value":"Journal of Pharmaceutical Sciences","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.xphs.2025.103999","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Inc. on behalf of American Pharmacists Association.","name":"copyright","label":"Copyright"}],"article-number":"103999"}}